Quote & Headlines
Market Currents
StockTalk
Description
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
432 people get OGXI articles and Market Currents by email alert.
Get email alerts on OGXI »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
Playing OncoGenex's ASCO DataJessica King Holden • Mon, Jun 4, 2012 -
OncoGenex Pharmaceuticals: Novel Products, Financial FlexibilityJason Chew • Wed, Dec 15, 2010
-
-
-
-
-
3 Healthcare Stocks With Strong Buy Analyst Ratings And Minimal DebtZetaKap • Thu, Aug 23, 2012 -
-
-
-
-
-
-
-
-
-
-
-
-
-
Life Technologies Could Open Doors For PharmaceuticalsJessica King Holden • Thu, Jan 12, 2012
-
-
OncoGenex Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptMon, May 10, 2010
-
PR Newswire (May 28, 2013)
-
PR Newswire (May 22, 2013)
-
PR Newswire (Apr 23, 2013)
-
PR Newswire (Mar 28, 2013)
-
PR Newswire (Feb 5, 2013)
-
at MarketWatch.com (Jan 2, 2013)
-
PR Newswire (Nov 9, 2012)
-
PR Newswire (Nov 6, 2012)
-
PR Newswire (Oct 30, 2012)
OGXI vs. ETF Alternatives
Company Description
Currently, there's no company description for OGXI.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, March 7, 5:14 PM OncoGenex Pharmaceuticals (OGXI): Q4 EPS of -$0.28 beats by $0.22. Revenue of $9.8M beats by $2.3M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, February 12, 1:14 PM OncoGenex Pharmaceuticals (OGXI +1.4%) trades up today after saying it's initiating Phase 2 clinical studies to evalutate OGX-427, a treatment for patients with advanced metastatic bladder cancer. The study is sponsored by Hoosier Oncology Group. Comment! [Healthcare, On the Move]
- Monday, February 4, 6:48 PM OncoGenex Pharmaceuticals (OGXI) says that CFO Michelle Burris has resigned that position after she and CEO Scott Cormack told the board last month about a developing personal relationship, which spurred directors to seek a transfer of executive duties. She'll serve as EVP of operations until March 31 and act as a consultant to the firm over the next year; the board tapped Cormack as Principal Financial Officer, Secretary and Treasurer, replacing Burris in those roles. Shares -3.4% AH. Comment! [Healthcare, On the Move]
- Friday, March 16, 2012, 9:39 AM OncoGenex Pharmaceuticals (OGXI -18.9%) dives after stating the share offering announced yesterday will involve selling 4.165M shares at a price of just $12. Even after today's crash, OncoGenex shares are changing hands at $14.47. Comment! [Healthcare, On the Move]
- Thursday, March 15, 2012, 4:23 PM OncoGenex Pharmaceuticals (OGXI +7.6%) falls 12.3% AH after filing for a stock offering featuring an undisclosed number of shares. The company plans to partly use the proceeds to develop its OGX-427 cancer drug, and possibly other drug candidates. Comment! [Healthcare, On the Move]
- Friday, August 5, 2011, 1:33 PM Shares of OncoGeneX (OGXI -24.3%) crater after the firm announces two of its drug-development programs for lung cancer will have delayed results. Interestingly, the share price started falling yesterday in advance of this morning's announcement. 1 Comment [On the Move, Healthcare]
-
Tuesday, October 19, 2010, 9:15 AM
Premarket gainers: CTIC +14%. MEE +10%. PH +9%. RNN +7%.
Losers: INFN -33%. CWTR -29%. OGXI -15%. KCI -13%. BXC -11%. HT -7%. BKCC -7%. NVO -7%. VMW -7%. AIB -6%. ABK -5%. RIO -5%. ALU -5%. AAPL -5%. HL -4%. IBM -4%. RCL -4%. AUY -4%. ARMH -4%. WFT -4%. BHP -4%. SLW -4%. TOT -4%. Comment! -
Monday, December 21, 2009, 9:00 AM
Premarket gainers: CHTT +33%. TEX +9%. BUCY +8%. INCY +6%. CTIC +5%. BCRX +4%. ABK +4%. AA +4%. CAG +4%.
Losers: OGXI -21%. IRE -9%. GIGM -7%. AIB -6%. LYG -5%. Comment!
-
ZetaKap
3 Healthcare Stocks With Strong Buy Analyst Ratings And Minimal Debt http://bit.ly/Pe3Lui $CO $LCI $OGXI @ZetaKap - View all 0 replies
-
- View all 1 replies
-
mdsoneta: I actually bought today @ 13.72. I think the prospect is good and their product is in third phase so reach around 20.00 by next year. GL.
-
Michael Kudrna
Biotech: OncoGeneX (OGXI) Q3-11 Earnings Conference Call Notes http://bit.ly/veJWBZ EXEL - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
mdsoneta: I actually bought today @ 13.72. I think the prospect is good and their product is in third phase so reach around 20.00 by next year. GL.